#1 Ranked Children’s Hospital by U.S. News & World Report
MyPatients provides referring primary care providers with secure access to their patients’ information.
Boston Children's has launched the world's 1st program dedicated to offering hand transplants to children who qualify.
Innovation insider is a semi-monthly e-newsletter analyzes innovations at Boston Children’s, other academic medical centers and from industry.
Read the latest blog by a Boston Children's doctor, clinician or staff member.
There are many ways you can help children and their families get the care they need.
While there is no known cure for CDKL5 disorder, the CDKL5 Clinic and its affiliated researchers are working hard to develop new treatment options. To set the stage for clinical treatment trials in the future, we are seeking to better understand the disorder’s natural progression and the complications that children can experience. Our laboratory research on the effects of the CDKL5 mutation will help guide these trials as well.
Two observational studies at Boston Children’s Hospital’s CDKL5 clinic are actively gathering information about the genetic variations that may contribute to the disorder and the clinical features that are associated with those variants. These studies are optional and are not required for care at the clinic. If you have questions about participating in our CDKL5 research studies, please contact the study coordinators at 617-355-5230 or by email at CDKL5@childrens.harvard.edu.
Boston Children’s Translational Neuroscience Center and F.M. Kirby Neurobiology Center have upcoming studies to better understand the biology of CDKL5 disease and its effects on visual processing. Read more about laboratory research on CDKL5.
Additional translational studies may be available soon. Please ask our team (617-355-5230 or via email).
Fehr S; et al. There is variability in the attainment of developmental milestones in the CDKL5 disorder. J Neurodev Disord 2015; 7:2. DOI: 10.1186/1866-1955-7-2
Fehr S; et al. The CDKL5 disorder is an independent clinical entity associated with early-onset encephalopathy. Eur J Hum Genet 2013 Mar; 21: 266–73.
Olson HE, Poduri A. CDKL5 mutations in early onset epilepsy: Case report and review of the literature. J Pediatr Epilep 2012: 1:151-9.
See more research publications on CDKL5.
We are grateful to have been ranked #1 on U.S. News & World Report's list of the best children's hospitals in the nation for the third year in a row, an honor we could not have achieved without the patients and families who inspire us to do our very best for them. Thanks to you, Boston Children's is a place where we can write the greatest children's stories ever told.”